GlassScriptPhysician profile
Bridget Dunn Webb
NPI 1801981675
$5,407.28
in general payments reported to CMS, 2019-2025
29 companies · $395 in 2025
The $395 reported for 2025 was more than what 77% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,560 · 2022: $1,763 · 2023: $1,072 · 2024: $618 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,375.66 | 2021-2025 | |
| Pfizer INC. | $654.93 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $425.96 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $277.48 | 2023-2025 | Gemtesa, Myfembree |
| Eisai INC. | $167.32 | 2021 | |
| Urovant Sciences INC | $158.25 | 2021-2022 | |
| Avion Pharmaceuticals | $157.12 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.71 | 2022 | |
| Myovant Sciences INC. | $138.85 | 2021-2022 | |
| Lilly USA, LLC | $135.25 | 2021-2025 | Zepbound |
| Ironwood Pharmaceuticals, INC | $123.88 | 2021-2023 | Linzess |
| Millicent US INC | $90.33 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Therapeuticsmd, INC. | $85.67 | 2021-2022 | |
| Bausch Health US, LLC | $79.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.97 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $48.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $44.58 | 2022 | |
| Exeltis, USA INC. | $38.35 | 2022 | |
| Acelrx Pharmaceuticals, INC. | $23.21 | 2021 | |
| Agile Therapeutics, INC. | $20.41 | 2021 | |
| Hologic Sales and Service, LLC | $19.56 | 2022 | |
| Virtus Pharmaceuticals LLC | $19.43 | 2021 | |
| Acella Pharmaceuticals, LLC | $19.03 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $17.47 | 2025 | Veozah |
| Musculoskeletal Transplant Foundation INC. | $17.41 | 2023 | |
| Dexcom, INC. | $17.34 | 2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $15.73 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.65 | 2025 | Unithroid |
| Scynexis, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.